A Phase 2 interventional study of B244 and Vehicle in Migraine, sponsored by AOBiome LLC. Completed at 22 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-04.
Sponsored by AOBiome LLC · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.
Among the 696 studies in Migraine Disorders with a site in United States, this one is the 155th largest by enrollment of the 609 interventional ones that give a count, is one of 27 that started in 2018, is one of 90 in phase 2, and was the 378th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Columbia University · Sites in United States
Ages 18–55
TriGemX Bio, Inc. · Sites in United States
Ages 18–75
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
696 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 113 · Phase 3 151 · Phase 4 101
First in 1999; this study’s year is marked. 27 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 313 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 78 across the 609 interventional studies, 195 across the 84 observational. Of the 526 that completed or were terminated, 305 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
344 of 696 have an industry lead sponsor. The 10 most frequent:
AOBiome LLC is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AOBiome LLC has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
47 of the studies in Migraine Disorders with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07645924Phase 3TriGemX Bio, Inc.A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | 2027-02 |
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 47 to your calendar (.ics) → With an account.
Among the 696 studies in Migraine Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, randomized, vehicle-controlled, double-blind, multi-center study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic migraine.
This is a Prospective, Randomized, Vehicle-controlled, Double-blind, Multi-center, 3-arm study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic migraine.
At Screening and Baseline, all subjects must experiences 4-14 migraine days per month and 3-14 migraine attacks per month and no more than 14 headache days per month in the 3 months prior to screening.
The total duration of the study will be approximately 16 weeks. Participants will report for a Screening visit and if all inclusion criteria are met, subjects will go through a one month baseline period prior to randomization. Subjects will come in for visits at Day 28 (Week 4), Day 56 (Week8), Day 84 (Week12), and Day 112 (Week 16).
Efficacy will be assessed by change in migraine attacks, days, and hours. Blood and urine samples will be collected for standard safety laboratory testing and the effect of the drug on inflammatory biomarkers. Safety will be monitored throughout the study.
Investigators plan to enroll 303 total subjects. Subjects will be randomized 1:1:1 so that an equal number of subjects will be treated in each arm of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
B244 1X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
Biological: B244
B244 4X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
Biological: B244
Vehicle, 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
Biological: Vehicle
B244 Suspension
Vehicle Suspension
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Safety and tolerability endpoints will consist of all adverse events reporting during the study duration.
Time frame: Baseline to Day 112
Mean Change in Monthly Migraine Days.
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine days (experiencing migraine with or without aura in a given day).
Time frame: Baseline to Day 84
Mean Change in Monthly Migraine Attacks.
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine attacks (an episode of any qualified migraine headache. To distinguish an attack of long duration from two attacks or to distinguish between attacks and relapses: A migraine attack that is interrupted by sleep, or temporarily remits, and then recurs within 48 hours (i.e., \<48 hours between the start of the migraine attack to the time of the recurrence) will be considered as one attack and not two. -An attack treated successfully with medication but with relapse within 48 hours (i.e., \<48 hours between the start of the migraine attack to the time of recurrence) will be considered as one attack.)
Time frame: Baseline to Day 84
Proportion of Subjects Experiencing a 50%, 75%, and 100% Reduction in Monthly Migraine Days.
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine days (experiencing migraine with or without aura in a given day).
Time frame: Baseline to Day 112
Mean Change in Monthly Acute Migraine Specific Medication Days.
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included use of rescue (acute migraine specific) medications and dosing administration.
Time frame: Baseline to Day 84
Mean Change in Monthly Headache Days.
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on headache days (a non-migraine headache day)
Time frame: Baseline to Day 84
Mean Change From Baseline to 12 Weeks of Treatment in Disability, as Measured by the Migraine Disability Assessment (MIDAS)
The Migraine Disability Assessment (MIDAS) questionnaire was administered to study examine the relationship between the impact of migraine and quality of life where subjects scored 5 questions on a scale of 0 to 21+ (0-5=little or no disability, 6-10=mild disability, 11-20=moderate disability, 21+=severe disability). The total score ranges from 0 to 90.
Time frame: Baseline to Day 84
Mean Change From Baseline to 12 Weeks of Treatment in Monthly Headache Impact Test-6 (HIT-6) Questionnaire
The Headache Impact Test-6 (HIT-6) questionnaire was administered to examine the relationship between impact of migraine and quality of life. The total score ranges from 36 to 78 where a higher score indicates a greater impact on quality of life (Class I: 36-49, Class II: 50-55, Class III: 56-59, Class IV: 60+).
Time frame: Baseline to Day 84
Mean Change From Baseline to 12 Weeks of Treatment in Monthly Migraine Specific Quality of Life Questionnaire (MSQL)
The Migraine Specific Quality of Life (MSQL) questionnaire was used to examine the impact of migraine on health-related quality of life across three domains: Role Function-Restrictive (7 questions) examines the degree to which performance of daily activities is limited by migraine; Role Function-Preventive (4 questions) examines the degree to which performance of daily activities is prevented by migraine; Emotional Function (3 questions) examines feelings of frustration and helplessness due to migraine. Total score for each domain ranges from 0 to 100, where a higher score indicates greater severity.
Time frame: Baseline to Day 84
Mean Change in Days Where Subject Recorded Migraine Associated Symptoms: Nausea/Vomiting, Photophobia and Sonophobia.
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine associated symptoms: nausea/vomiting, photophobia and sonophobia.
Time frame: Baseline to Day 112
| Milestone | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| Started | 105 | 104 | 104 |
| Completed | 83 | 88 | 81 |
| Not completed | 22 | 16 | 23 |
| Withdrew: Lost to follow-up | 7 | 6 | 7 |
| Withdrew: Withdrawal by subject | 8 | 7 | 7 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Protocol violation | 3 | 2 | 6 |
| Withdrew: Subject did not meet minimum number of migraines per month | 1 | 0 | 0 |
| Withdrew: Use of prohibited medication | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 |
| Withdrew: Subject returned for et visit | 0 | 1 | 0 |
| Withdrew: Sponsor's decision | 0 | 0 | 1 |
Safety and tolerability endpoints will consist of all adverse events reporting during the study duration.
| Participants | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| At Least 1 Treatment-Related TEAE | 18 | 13 | 17 |
| At Least 1 Treatment-Related Grade 3 or 4 TEAE | 1 | 0 | 1 |
| At Least 1 Treatment-Related Serious TEAE | 0 | 0 | 0 |
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine days (experiencing migraine with or without aura in a given day).
| days per month | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| Mean Change in Monthly Migraine Days. | -3.2 ± 4.53 | -3.0 ± 4.04 | -3.4 ± 3.77 |
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine attacks (an episode of any qualified migraine headache. To distinguish an attack of long duration from two attacks or to distinguish between attacks and relapses: A migraine attack that is interrupted by sleep, or temporarily remits, and then recurs within 48 hours (i.e., \<48 hours between the start of the migraine attack to the time of the recurrence) will be considered as one attack and not two. -An attack treated successfully with medication but with relapse within 48 hours (i.e., \<48 hours between the start of the migraine attack to the time of recurrence) will be considered as one attack.)
| attacks | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| Mean Change in Monthly Migraine Attacks. | -2.0 ± 2.83 | -2.1 ± 2.43 | -2.0 ± 2.69 |
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine days (experiencing migraine with or without aura in a given day).
| Participants | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| Week 12 : ≥50% Reduction | 31 | 36 | 32 |
| Week 12 : ≥75% Reduction | 20 | 17 | 17 |
| Week 12 : 100% Reduction | 10 | 8 | 7 |
| Week 16 : ≥50% Reduction | 24 | 20 | 20 |
| Week 16 : ≥75% Reduction | 12 | 7 | 12 |
| Week 16 : 100% Reduction | 10 | 3 | 3 |
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included use of rescue (acute migraine specific) medications and dosing administration.
| days | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| Mean Change in Monthly Acute Migraine Specific Medication Days. | -2.0 ± 5.62 | -2.5 ± 3.70 | -2.9 ± 4.26 |
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on headache days (a non-migraine headache day)
| days | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| Mean Change in Monthly Headache Days. | -3.5 ± 4.66 | -3.4 ± 3.96 | -4.2 ± 3.79 |
The Migraine Disability Assessment (MIDAS) questionnaire was administered to study examine the relationship between the impact of migraine and quality of life where subjects scored 5 questions on a scale of 0 to 21+ (0-5=little or no disability, 6-10=mild disability, 11-20=moderate disability, 21+=severe disability). The total score ranges from 0 to 90.
| score on a scale | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| Mean Change From Baseline to 12 Weeks of Treatment in Disability, as Measured by the Migraine Disability Assessment (MIDAS) | -10.0 ± 24.83 | -18.0 ± 39.43 | -13.8 ± 23.82 |
The Headache Impact Test-6 (HIT-6) questionnaire was administered to examine the relationship between impact of migraine and quality of life. The total score ranges from 36 to 78 where a higher score indicates a greater impact on quality of life (Class I: 36-49, Class II: 50-55, Class III: 56-59, Class IV: 60+).
| score on a scale | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| Mean Change From Baseline to 12 Weeks of Treatment in Monthly Headache Impact Test-6 (HIT-6) Questionnaire | -4.3 ± 6.72 | -6.2 ± 7.68 | -5.7 ± 7.54 |
The Migraine Specific Quality of Life (MSQL) questionnaire was used to examine the impact of migraine on health-related quality of life across three domains: Role Function-Restrictive (7 questions) examines the degree to which performance of daily activities is limited by migraine; Role Function-Preventive (4 questions) examines the degree to which performance of daily activities is prevented by migraine; Emotional Function (3 questions) examines feelings of frustration and helplessness due to migraine. Total score for each domain ranges from 0 to 100, where a higher score indicates greater severity.
| score on a scale | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| Role Function-Restrictive | 15.5 ± 18.00 | 22.7 ± 23.69 | 22.3 ± 24.53 |
| Role Function-Preventive | 10.7 ± 16.89 | 16.1 ± 22.21 | 12.5 ± 22.04 |
| Emotional Function | 11.8 ± 24.77 | 19.0 ± 27.16 | 20.2 ± 27.95 |
Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine associated symptoms: nausea/vomiting, photophobia and sonophobia.
| days | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| Change from Baseline to Week 12 | -2.3 ± 4.68 | -2.8 ± 3.49 | -2.9 ± 3.56 |
| Change from Baseline to Week 16 | -1.6 ± 4.61 | -2.0 ± 3.93 | -1.6 ± 4.21 |
Collected over Baseline to Day 112. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B244 Dose 1 | 0/105 (0%) | 3/105 (2.9%) | 45/105 (42.9%) |
| B244 Dose 2 | 0/104 (0%) | 0/104 (0%) | 42/104 (40.4%) |
| Vehicle | 0/104 (0%) | 0/104 (0%) | 49/104 (47.1%) |
| Event | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/105 | 0/104 | 0/104 |
| CholelithiasisHepatobiliary disorders | 1/105 | 0/104 | 0/104 |
| Event | B244 Dose 1 | B244 Dose 2 | Vehicle |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/105 | 10/104 | 4/104 |
| NasopharyngitisInfections and infestations | 3/105 | 2/104 | 5/104 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 5/105 | 4/104 | 1/104 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/105 | 4/104 | 3/104 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/105 | 3/104 | 4/104 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/105 | 3/104 | 1/104 |
| InfluenzaInfections and infestations | 3/105 | 1/104 | 1/104 |
| Nasal drynessRespiratory, thoracic and mediastinal disorders | 3/105 | 1/104 | 2/104 |
| SneezingRespiratory, thoracic and mediastinal disorders | 3/105 | 0/104 | 1/104 |
| BronchitisInfections and infestations | 1/105 | 2/104 | 1/104 |
Intent-to-Treat Population included all randomized subjects who received at least 1 dose of IP and had 80% ePRO diary compliance. Subjects were analyzed according to the treatment assigned by the randomization schedule.
| Age, Customized(Participants) | B244 Dose 1 | B244 Dose 2 | Vehicle | Total |
|---|---|---|---|---|
| <30 | 16 | 12 | 16 | 44 |
| ≥30 | 76 | 82 | 72 | 230 |
| Sex: Female, Male(Participants) | B244 Dose 1 | B244 Dose 2 | Vehicle | Total |
|---|---|---|---|---|
| Female | 82 | 76 | 76 | 234 |
| Male | 10 | 18 | 12 | 40 |
| Ethnicity (NIH/OMB)(Participants) | B244 Dose 1 | B244 Dose 2 | Vehicle | Total |
|---|---|---|---|---|
| Hispanic or Latino | 10 | 10 | 14 | 34 |
| Not Hispanic or Latino | 82 | 84 | 72 | 238 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | B244 Dose 1 | B244 Dose 2 | Vehicle | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 3 | 1 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 27 | 21 | 20 | 68 |
| White | 61 | 69 | 66 | 196 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 3 | 0 | 4 |
| Weight(kg) | B244 Dose 1 | B244 Dose 2 | Vehicle | Total |
|---|---|---|---|---|
| Mean | 85.09 ± 25.835 | 93.33 ± 22.791 | 89.34 ± 25.940 | 85.85 ± 24.903 |
| Height(m) | B244 Dose 1 | B244 Dose 2 | Vehicle | Total |
|---|---|---|---|---|
| Mean | 1.66 ± 0.084 | 1.66 ± 0.111 | 1.66 ± 0.089 | 1.66 ± 0.095 |
| BMI(kg/m^2) | B244 Dose 1 | B244 Dose 2 | Vehicle | Total |
|---|---|---|---|---|
| Mean | 30.51 ± 8.569 | 30.55 ± 9.183 | 31.99 ± 8.229 | 31.00 ± 8.675 |
| BMI Category(Participants) | B244 Dose 1 | B244 Dose 2 | Vehicle | Total |
|---|---|---|---|---|
| <20 kg/m^2 | 2 | 3 | 2 | 7 |
| 20-<25 kg/m^2 | 23 | 26 | 17 | 66 |
| 25-<30 kg/m^2 | 30 | 20 | 19 | 69 |
| ≥30 kg/m^2 | 37 | 45 | 50 | 132 |
12 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Jun 2019, 14 months.
Results were first posted in Oct 2022, 3 years 3 months after primary completion. A results delay was requested in Jul 2020.
Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 14 months is above that.
Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitrosomonas eutropha D23
AOBiome LLC